Glial Cells: Physiological and Pathological Perspective

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Nervous System".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 854

Special Issue Editor


E-Mail Website
Guest Editor
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Interests: glia cells; myelination; neurodegenerative diseases; cancer neuroscience
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases of the central nervous system (CNS), including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), are characterized by progressive neuronal loss and dysfunction. Glial cells, comprising astrocytes, microglia, oligodendrocytes, and ependymal cells, play crucial roles in maintaining CNS homeostasis, neuronal support, and response to injury. Emerging evidence implicates glial cells as central players in the pathogenesis of neurodegenerative diseases. Astrocytes contribute to neuroinflammation and neuroprotection, yet their dysfunction can exacerbate neuronal damage. Microglia, the resident immune cells of the CNS, are pivotal in mediating inflammatory responses. Oligodendrocytes, responsible for myelination, are affected in diseases such as multiple sclerosis, where demyelination impairs neural conductivity and leads to neurodegeneration. Additionally, the interactions between glial cells and neurons are critical in modulating the progression of disease. Understanding the molecular mechanisms governing glial cell function and dysfunction would provide insights into the complex interplay between these cells and neurons in neurodegenerative diseases. This knowledge is pivotal for developing glia-targeted therapies that are aimed at modulating glial activity in order to ameliorate disease progression and promote neuroprotection in the fight against neurodegenerative diseases.

Dr. Qing Richard Lu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • oligodendrocytes
  • astrocytes
  • microglia
  • neuroinflammation
  • demyelination neuron–glial interactions
  • homeostasis
  • glia-targeted therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

29 pages, 27509 KiB  
Article
Repurposed Drugs to Enhance the Therapeutic Potential of Oligodendrocyte Precursor Cells Derived from Adult Rat Adipose Tissue
by J. Pascual-Guerra, M. Torres-Rico, B. Marín-Rodríguez, M. S. Arasmou-Idrovo, A. G. García, J. A. Rodríguez-Navarro and C. L. Paíno
Cells 2025, 14(7), 533; https://doi.org/10.3390/cells14070533 - 2 Apr 2025
Viewed by 582
Abstract
Failure in the proliferation, recruitment, mobilization, and/or differentiation of oligodendrocyte precursor cells (OPCs) impedes remyelination in central nervous system (CNS) demyelinating diseases. Our group has recently achieved the generation of functional oligodendroglia through direct lineage conversion by expressing Sox10, Olig2, and [...] Read more.
Failure in the proliferation, recruitment, mobilization, and/or differentiation of oligodendrocyte precursor cells (OPCs) impedes remyelination in central nervous system (CNS) demyelinating diseases. Our group has recently achieved the generation of functional oligodendroglia through direct lineage conversion by expressing Sox10, Olig2, and Zfp536 genes in adult rat adipose tissue-derived stromal cells. The present study aimed to determine whether various repurposed drugs or molecules could enhance the myelinating capacities of these induced OPCs (iOPCs). We report that kainate, benztropine, miconazole, clobetasol, and baclofen promote in vitro iOPCs migration, differentiation, and ensheathing abilities through mechanisms similar to those observed in rat neural stem cell-derived OPCs. This research supports the potential use of iOPCs as they provide an alternative and reliable cell source for testing the effects of in vitro promyelinating repurposed drugs and for assessing the molecular and cellular mechanisms involved in therapeutic strategies for demyelinating diseases. Full article
(This article belongs to the Special Issue Glial Cells: Physiological and Pathological Perspective)
Show Figures

Graphical abstract

Back to TopTop